Governments have adopted these policies due to a combination of factors, such as environmental concerns, high oil prices, and less dependence on imported oil.Among the fuels other than traditional petroleum fuels (gasoline or diesel fuel), and alternative technologies for powering the engine of a motor vehicle, the most popular options promoted by different governments are: natural gas vehicles,  LPG powered vehicles, flex-fuel vehicles, use of biofuels, hybrid electric vehicles, plug-in hybrids, electric cars, and hydrogen fuel cell cars.Since the late 2000s, China, European countries, the United States, Canada, Japan and other developed countries have been providing strong financial incentives to promote the adoption of plug-in electric vehicle. As of 2020, the stock of light-duty plug-in vehicles in use totaled over 10 million units. As of 2019, in addition, the medium and heavy commercial segments add another 700,000 units to the global stock of plug-in electric vehicles. In 2020 the global market share of plug-in passenger car sales was 4.2%, up from 2.5% in 2019. Nevertheless, despite government support and the rapid growth experienced, the plug-in electric car segment represented just about 1 out of every 250 vehicles (0.4%) on the worlds roads by the end of 2018. China
The Peoples Republic of China had 322 million motor vehicles in use at the end of September 2018, of which, 235 million were passenger cars in 2018, making China the country with largest motor vehicle fleet in the world. In 2016, the motor vehicle fleet consisted of 165.6 million cars and 28.4 million trucks and buses.
Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate. Approval
On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain. It is marketed by Alcon under the tradename Durezol. Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a phase 3 study evaluating difluprednate for the treatment of anterior uveitis


== References ==